{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 450848962
| ImageFile=Senicapoc.png
| ImageSize=200px
| IUPACName=2,2-bis(4-fluorophenyl)-2-phenylacetamide
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TS6G201A6Q
| IUPHAR_ligand = 2331
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=289656-45-7
| PubChem=216327
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06640
| SMILES=C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 187516
| InChI = 1/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
| InChIKey = SCTZUZTYRMOMKT-UHFFFAOYAR
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = SCTZUZTYRMOMKT-UHFFFAOYSA-N
  }}
|Section2={{Chembox Properties
| Formula=C<sub>20</sub>H<sub>15</sub>F<sub>2</sub>NO
| MolarMass=323.34 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Senicapoc''' (ICA-17043) is a Gardos channel blocker.<ref name="pmid18192510">{{cite journal  |vauthors=Ataga KI, Smith WR, De Castro LM, etal |title=Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia |journal=Blood |volume=111 |issue=8 |pages=3991–7 |date=April 2008 |pmid=18192510 |doi=10.1182/blood-2007-08-110098 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=18192510}}</ref><ref name="pmid18232633">{{cite journal  |vauthors=McNaughton-Smith GA, Burns JF, Stocker JW, etal |title=Novel inhibitors of the Gardos channel for the treatment of sickle cell disease |journal=J. Med. Chem. |volume=51 |issue=4 |pages=976–82 |date=February 2008 |pmid=18232633 |doi=10.1021/jm070663s}}</ref>

It has been proposed for use in [[sickle cell anemia]].<ref name="pmid19236269">{{cite journal |author1=Ataga KI |author2=Stocker J |title=Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia |journal=Expert Opin Investig Drugs |volume=18 |issue=2 |pages=231–9 |date=February 2009 |pmid=19236269 |doi=10.1517/13543780802708011 |url=http://www.informapharmascience.com/doi/abs/10.1517/13543780802708011	}}</ref>

The Gardos channel has been identified as [[KCNN4]].<ref name="pmid12773623">{{cite journal |author1=Hoffman JF |author2=Joiner W |author3=Nehrke K |author4=Potapova O |author5=Foye K |author6=Wickrema A |title=The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=100 |issue=12 |pages=7366–71 |date=June 2003 |pmid=12773623 |pmc=165881 |doi=10.1073/pnas.1232342100 |url=http://www.pnas.org/cgi/pmidlookup?view=long&pmid=12773623}}</ref>

The "ICA" is for [[Icagen]], which is developing the drug.<ref name="urlIcagen - Press Release">{{cite web |url=http://ir.icagen.com/phoenix.zhtml?c=178443&p=irol-newsArticle&ID=1207330&highlight= |title=Icagen - Press Release |format= |work= |accessdate=2008-12-22}}</ref>

==References==
{{reflist}}

[[Category:Fluoroarenes]]
[[Category:Acetamides]]


{{blood-drug-stub}}